Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
4.950
-0.060 (-1.20%)
Nov 21, 2024, 1:39 PM EST - Market open
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Nevan Elam |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 206 4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nevan Charles Elam J.D. | Founder, Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board |
| Daron G. Evans M.B.A., M.S. | Chief Financial Officer |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific and Patient Affairs |
| Michael R. Deperro | Senior Vice President and Head of Corporate Development |
| Michael Covarrubias | Senior Vice President and Head of Program & Portfolio Management |
| Chris Milks | Vice President and Head of Finance |
| Dr. Raj Agrawal M.D. | Vice President and Head of Ophthalmological Clinical Development |
| Robyn Sweinhart | Vice President and Head of Quality |
| Erin O'Boyle | Senior Vice President and Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 21, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 10, 2024 | PRE 14A | Other preliminary proxy statements |